ClinicalTrials.gg
CompletedNCT01995617Updated Dec 11, 2015

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

A Phase 1 interventional study of Placebo and GEN-004 Low Dose in Streptococcus Pneumoniae, sponsored by Genocea Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-11.

Sponsored by Genocea Biosciences, Inc. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

GEN-004 is a combination of 3 conserved proteins from Streptococcus pneumoniae. This is a randomized, double-blind, placebo-controlled, dose escalation study. Eligible subjects (male and non-pregnant female) will be assigned sequentially to 1 of 3 dose cohorts and randomized in a 3:1:1 ratio to receive GEN-004 with adjuvant, GEN-004 without adjuvant, or placebo, respectively. Each subject will receive up to 3 doses at 4 week intervals.

Subjects will be followed for safety, tolerability, and immunogenicity for 12 months after their last dose.

02

Conditions studied

  • Streptococcus Pneumoniae

Keywords

  • vaccine
  • Streptococcus pneumoniae
  • Strep pneumo
03

In context

Lead sponsor

Genocea Biosciences, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and non-pregnant females, ages 18 to 55 years inclusive.
  2. Willing and able to provide written .
  3. Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
  4. Willing to practice adequate that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, barrier methods such as condoms, diaphragms, intrauterine devices, and licensed hormonal methods for 28 days before and 90 days after receiving Study Drug.

Exclusion criteria

Exclusion Criteria:

  1. individuals, including those receiving immunosuppressive doses of (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 µg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents.
  2. Presence or history of disease, regardless of current treatment.
  3. Insulin dependent diabetes.
  4. Positive serologic test for -1 or infection; positive surface antigen (HBsAg).
  5. Screening serum chemistry or hematology abnormality ≥ Grade 1.
  6. Screening urinalysis abnormality ≥ Grade 2.
  7. Positive urine drug screen or alcohol Breathalyzer test at Screening or on Study Day 1.
  8. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements.

    NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.

  9. Any acute illness including, fever (>100.4 degrees F [> 38 degrees C]) within 3 days prior to the first dose of Study Drug.
  10. Pregnant or nursing women.
  11. Receipt of any drug within 30 days prior to the first dose of Study Drug.
  12. Receipt of blood products within 90 days prior to the first dose of Study Drug.
  13. Donation of blood or plasma within 56 days prior to Screening.
  14. Receipt of a within 28 days prior or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug.
  15. Prior vaccination with pneumococcal vaccine.
  16. History of to any component of the vaccine or history of an allergic reaction to an immunization.
  17. History of invasive pneumococcal disease (i.e., sepsis, meningitis or pneumonia with bacteremia).
  18. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the subject's ability to comply with the study requirements.
  19. Any other condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Low Dose (Cohort 1)

    Biological: Placebo · Biological: GEN-004 Low Dose · Biological: GEN-004 Low Dose + Adjuvant

  • Experimental
    Mid Dose (Cohort 2)

    Biological: Placebo · Biological: GEN-004 Mid Dose · Biological: GEN-004 Mid Dose + Adjuvant

  • Experimental
    High Dose (Cohort 3)

    Biological: Placebo · Biological: GEN-004 High Dose · Biological: GEN-004 High Dose + Adjuvant

Interventions

  • BiologicalPlacebo

    normal saline, 0.5 mL per dose

  • BiologicalGEN-004 Low Dose

    The GEN-004 Low Dose contains 10µg of each of the three antigens.

  • BiologicalGEN-004 Low Dose + Adjuvant

    Drug page: Adjuvant

    The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

  • BiologicalGEN-004 Mid Dose

    The GEN-004 Mid Dose contains 30µg of each of the three antigens.

  • BiologicalGEN-004 Mid Dose + Adjuvant

    Drug page: Adjuvant

    The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

  • BiologicalGEN-004 High Dose

    The GEN-004 High Dose contains 100µg of each of the three antigens.

  • BiologicalGEN-004 High Dose + Adjuvant

    Drug page: Adjuvant

    The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of GEN-004 when administered with and without aluminum hydroxide to adult subjects.

    Time frame: 12 months after third (last) dose

Secondary outcomes

  1. To evaluate the immunogenicity of GEN-004, as measured by TH17 (IL-17) and IgG responses to the antigens, when administered with and without aluminum hydroxide.

    Time frame: 12 months after third (last) dose

  2. To evaluate the durability of immune responses up to 12 months after the last dose.

    Time frame: 12 months after third (last) dose

07

Study locations

1 site
  • Prism Research
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2013
First posted
Nov 26, 2013
Start
Nov 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Dec 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01995617
Lead sponsor
Genocea Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Nov 2013
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Dec 11, 2015

Study contacts

Mark Matson, MD
principal investigator · Prism Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adjuvant

Start the discussion